Key Highlights

  • Rentokil Initial spent the past two years living down one of the FTSE 100's more painful de-ratings.
  • The pest-control and hygiene group's roughly $6.7bn Takeover of US rival Terminix in 2022 was meant to create an unassailable North American leader; instead.
  • Group Revenue rose to $3,589m, up 6.7% reported and 4.5% at constant currency, with organic growth of 3.6%.
  • Adjusted operating profit increased 6.6% in constant currency to $556m and the Margin edged up to 15.5%.

Rentokil Initial spent the past two years living down one of the FTSE 100's more painful de-ratings. The pest-control and hygiene group's roughly $6.7bn takeover of US rival Terminix in 2022 was meant to create an unassailable North American leader; instead, integration wobbles and slowing American Demand shredded its once-premium valuation. Its half-year results on 30 July 2026 captured the comeback challenge in miniature: solid profitability and cash generation, but growth soft enough that management retired a flagship margin target — and the shares fell. The episode crystallised the central debate over whether the Terminix deal will ultimately create or destroy value.

The half-year picture

Group revenue rose to $3,589m, up 6.7% reported and 4.5% at constant currency, with organic growth of 3.6%. Adjusted operating profit increased 6.6% in constant currency to $556m and the margin edged up to 15.5%. The problem sat in the engine room: North America, the division that justified the Terminix deal, grew organic revenue just 3.7%, with core pest-control services up only 2.6%, and management flagged weak residential lead-flow into July. Adjusted Earnings Per Share rose 8.3% and the Interim Dividend was lifted 8%, a signal that the board remains confident in the group's cash generation even as top-line growth disappoints. Because so much of Rentokil's revenue is contracted and recurring, modest organic growth still translates into dependable cash, but the market has come to expect the mid-single-digit expansion that would justify a growth rating rather than the low-single-digit rate the US Business is currently delivering.

The retired target

The strategic headline-grabber was the decision to scrap the target of a 20% North America margin by 2027, with management saying it would prioritise Volume growth over near-term margin expansion. Presented as a sensible reordering of priorities, the market read it as an admission that the ambitious post-Terminix synergy goals were slipping. Rebuilding a premium rating requires convincing investors that abandoning the target buys durable, faster organic growth rather than simply lowering the bar the company had set for itself. Until the North American business shows it can consistently grow lead-flow and retain customers, scepticism about the deal's returns is likely to persist.

Business model

The underlying business remains attractive. Pest control is a recurring, contracted, largely non-discretionary service with high customer retention and pricing power, and Rentokil is the global number one, complemented by its Initial hygiene and workwear arms. North America is a huge, fragmented market that still offers years of consolidation opportunity through bolt-on acquisitions. The bull case rests on the density and route-efficiency advantages that scale in pest control can deliver once the Terminix branches are fully integrated and colleague retention stabilises across the enlarged US network. Higher technician retention lowers hiring and Training costs and improves service continuity, both of which feed directly into margins and into the customer relationships that make pest control such a resilient, repeat-revenue business.

Outlook

On the balance sheet, Rentokil generated free Cash Flow of $318m, up 12.8%, and ended the half with net Debt of $3,575m, or 2.4x EBITDA — within its 2.0-2.5x target range but leaving limited room for large deals until Leverage eases. Management reaffirmed that full-year 2026 profit should land in line with market expectations. The high-single-digit dividend growth signals confidence, but deleveraging and cash conversion will stay closely watched given the debt taken on for Terminix. Risks include further weakness in US residential demand, a soft consumer backdrop, integration execution, foreign-exchange translation and the competitive intensity of American pest control. Potential catalysts include stabilising North American lead-flow, evidence of improving colleague retention and route density, and a return to mid-single-digit organic growth. The key question is whether 2026 marks the base from which Rentokil rebuilds credibility — or another staging post in a longer recovery than the market once assumed.